Literature DB >> 26732437

A phase I study of elesclomol sodium in patients with acute myeloid leukemia.

David Hedley, Aisha Shamas-Din, Sue Chow, Deborah Sanfelice, Andre C Schuh, Joseph M Brandwein, Matthew D Seftel, Vikas Gupta, Karen W L Yee, Aaron D Schimmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26732437     DOI： 10.3109/10428194.2016.1138293

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  9 in total

1.  Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Authors:  Vikram B Wali; Casey G Langdon; Matthew A Held; James T Platt; Gauri A Patwardhan; Anton Safonov; Bilge Aktas; Lajos Pusztai; David F Stern; Christos Hatzis
Journal:  Cancer Res       Date:  2016-11-21       Impact factor: 12.701

Review 2.  Autophagy: In the cROSshairs of cancer.

Authors:  Heather Graham Hambright; Rita Ghosh
Journal:  Biochem Pharmacol       Date:  2016-10-24       Impact factor: 5.858

3.  Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.

Authors:  Yongyun Li; Jie Yang; Qianqian Zhang; Shiqiong Xu; Wei Sun; Shengfang Ge; Xiaowei Xu; Martine J Jager; Renbing Jia; Jianming Zhang; Xianqun Fan
Journal:  Oncogene       Date:  2022-06-13       Impact factor: 8.756

4.  The Anticancer Agent Elesclomol Has Direct Effects on Mitochondrial Bioenergetic Function in Isolated Mammalian Mitochondria.

Authors:  Josephine S Modica-Napolitano; Leena P Bharath; Alison J Hanlon; Liam D Hurley
Journal:  Biomolecules       Date:  2019-07-24

Review 5.  Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.

Authors:  Peijie Zheng; Chuntao Zhou; Liuyi Lu; Bin Liu; Yuemin Ding
Journal:  J Exp Clin Cancer Res       Date:  2022-09-12

Review 6.  Copper metabolism as a unique vulnerability in cancer.

Authors:  Vinit C Shanbhag; Nikita Gudekar; Kimberly Jasmer; Christos Papageorgiou; Kamal Singh; Michael J Petris
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-10-20       Impact factor: 4.739

Review 7.  Copper Coordination Compounds as Biologically Active Agents.

Authors:  Olga Krasnovskaya; Alexey Naumov; Dmitry Guk; Peter Gorelkin; Alexander Erofeev; Elena Beloglazkina; Alexander Majouga
Journal:  Int J Mol Sci       Date:  2020-05-31       Impact factor: 5.923

8.  Elesclomol restores mitochondrial function in genetic models of copper deficiency.

Authors:  Shivatheja Soma; Andrew J Latimer; Haarin Chun; Alison C Vicary; Shrishiv A Timbalia; Aren Boulet; Jennifer J Rahn; Sherine S L Chan; Scot C Leary; Byung-Eun Kim; Jonathan D Gitlin; Vishal M Gohil
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

Review 9.  Current Biomedical Use of Copper Chelation Therapy.

Authors:  Silvia Baldari; Giuliana Di Rocco; Gabriele Toietta
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.